Author: Sonti, Rajiv; Pike, C. William; Cobb, Nathan
Title: Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19 Cord-id: hth590jy Document date: 2020_11_25
ID: hth590jy
Snippet: BACKGROUND: Inhaled pulmonary vasodilators are used as adjunctive therapies for the treatment of refractory hypoxemia. Available evidence suggest they improve oxygenation in a subset of patients without changing long-term trajectory. Given the differences in respiratory failure due to COVID-19 and “traditional†ARDS, we sought to identify their physiologic impact. METHODS: This is a retrospective observational study of patients mechanically ventilated for COVID-19, from the ICUs of 2 tertiar
Document: BACKGROUND: Inhaled pulmonary vasodilators are used as adjunctive therapies for the treatment of refractory hypoxemia. Available evidence suggest they improve oxygenation in a subset of patients without changing long-term trajectory. Given the differences in respiratory failure due to COVID-19 and “traditional†ARDS, we sought to identify their physiologic impact. METHODS: This is a retrospective observational study of patients mechanically ventilated for COVID-19, from the ICUs of 2 tertiary care centers, who received inhaled epoprostenol (iEpo) for the management of hypoxemia. The primary outcome is change in PaO(2)/FiO(2). Additionally, we measured several patient level features to predict iEpo responsiveness (or lack thereof). RESULTS: Eighty patients with laboratory confirmed SARS-CoV2 received iEpo while mechanically ventilated and had PaO(2)/FiO(2) measured before and after. The median PaO(2)/FiO(2) prior to receiving iEpo was 92 mmHg and interquartile range (74 – 122). The median change in PaO(2)/FiO(2) was 9 mmHg (-9 – 37) corresponding to a 10% improvement (-8 – 41). Fifty-percent (40 / 80) met our a priori definition of a clinically significant improvement in PaO(2)/FiO(2) (increase in 10% from the baseline value). Prone position and lower PaO(2)/FiO(2) when iEpo was started predicted a more robust response, which held after multivariate adjustment. For proned individuals, improvement in PaO(2)/FiO(2) was 14 mmHg (-6 to 45) vs. 3 mmHg (-11 – 20), p = 0.04 for supine individuals; for those with severe ARDS (PaO(2)/FiO(2) < 100, n = 49) the median improvement was 16 mmHg (-2 – 46). CONCLUSION: Fifty percent of patients have a clinically significant improvement in PaO(2)/FiO(2) after the initiation of iEpo. This suggests it is worth trying as a rescue therapy; although generally the benefit was modest with a wide variability. Those who were prone and had lower PaO(2)/FiO(2) were more likely to respond.
Search related documents:
Co phrase search for related documents- acute ards respiratory distress syndrome and adjunct therapy: 1, 2, 3
- acute ards respiratory distress syndrome and logistic model: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute ards respiratory distress syndrome and long term outcome: 1, 2, 3, 4, 5, 6, 7
- acute ards respiratory distress syndrome and lung compliance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49
- acute ards respiratory distress syndrome and lung mechanic: 1
- acute ards respiratory distress syndrome and lung protective ventilation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- additional covariate and logistic model: 1
- additional study and lung compliance: 1
- adjunct therapy and lung compliance: 1
- logistic model and long term outcome: 1, 2, 3
- logistic model and lung compliance: 1
- long term outcome and lung compliance: 1, 2
- long term outcome and lung protective ventilation: 1, 2
Co phrase search for related documents, hyperlinks ordered by date